

©This material is subject to copyright.

Patients have authorized the reproduction for research and teaching.

Any other use is forbidden.

# CUTANEOUS REACTIONS AFTER SARS-COV-2 VACCINATION: A CROSS-SECTIONAL SPANISH NATIONWIDE STUDY OF 405 CASES

ALBA CATALÀ, CARLOS MUÑOZ-SANTOS, CRISTINA GALVÁN-CASAS, MÓNICA RONCERO RIESCO, DAVID REVILLA NEBREDÀ, AMADOR SOLÀ-TRUYOLS, PRISCILA GIAVEDONI, MAR LLAMAS VELASCO, CARLOS GONZÁLEZ-CRUZ, XAVIER CUBIRÓ, RICARDO RUÍZ-VILLAVERDE, SARA GÓMEZ ARMAYONES, MARÍA DEL PINO GIL MATEO, DAVID PESQUÉ, ORIANNA MARCANTONIO, DIEGO FERNÁNDEZ-NIETO, JORGE ROMANÍ, NICOLÁS IGLESIAS PENA, LUCÍA CARNERO GONZALEZ, JESÚS TERCEDOR, GREGORIO CARRETERO, TERESA MASAT, PEDRO RODRÍGUEZ JIMÉNEZ, ANA MARÍA GIMENEZ-ARNAU, MARTA UTRERA BUSQUETS, ELENA VARGAS LAGUNA, ANA G. ANGULO MENÉNDEZ, ELIANA SAN JUAN, MARIBEL IGLESIAS SANCHO, LAURA ALONSO NARANJO, INGRID HILTUN, EUGENIA CUTILLAS MARCO, ISABEL POLIMON OLABARRIETA, SILVIA MARINERO ESCOBEDO, XAVIER GARCÍA NAVARRO, MARÍA JOSÉ CALDERÓN GUTIÉRREZ, GLORIA BAEZA HERNÁNDEZ, LOLA BOU CAMPOS, TOMÁS TOLEDO PASTRANA. ANTONIO GUILABERT.

# INDEX


Covid-Arm _____	1
Urticaria and/or Angioedema _____	2
Morbilliform _____	3
Papulovesicular _____	4
Pityriasis rosea-like _____	5
Purpuric _____	6
Varicella zoster virus reactivation _____	7
Herpes simplex virus reactivation _____	8
Other eruptions _____	9

# SUPPLEMENTARY MATERIAL: PHOTOGRAPHIC ATLAS

## Covid-Arm




a. 64-year-old woman. Covid-arm. Onset 2 days after AZD1222 first dose. Resolved in 12 days. No treatment.



b. 62-year-old woman. Delayed covid-arm. Onset 9 days after mRNA-127 vaccine first dose. Resolved in 7 days. Treatment: NSAIDs and cold packs. Published by the present authors in <https://doi.org/10.1016/j.ad.2021.05.011>



c. 71-year-old woman. Delayed covid-arm. Onset 7 days after mRNA-127 first dose vaccine. Resolved in 7 days. Treatment: topical corticosteroids.



d. 61-year-old woman. Bullous covid-arm. Onset 1 day after AZD1222 first dose. Resolved in 15 days. Treatment: paracetamol.



e. 51-year-old woman. Covid-arm. Onset 1 day after mRNA-127 first dose vaccine. Resolved in 5 days. Treatment: paracetamol.

# SUPPLEMENTARY MATERIAL: PHOTOGRAPHIC ATLAS

## Urticaria and/or Angioedema




a. 66-year-old woman. Acute urticaria. Onset 24h after AZD1222 first dose. Resolved in 7 days. Treatment: oral antihistamines.

b. 27-year-old man. Acute urticaria. Onset 6 days after AZD1222 first dose vaccine. Treatment: oral antihistamines and topical corticosteroids.



c. 28-year-old woman. Acute urticaria. Onset 6 days after mRNA-127 second dose. Treatment: oral antihistamines.



d. 38-year-old woman. Acute angioedema. Onset 2 days after BNT162b2 second dose. Resolved in 24h. Treatment: endovenous antihistamines.




e. 34-year-old man. Acute urticaria. Onset 3 days after BNT162b2 second dose. Resolved in 35 days. Treatment: oral antihistamines and oral corticosteroids.




# SUPPLEMENTARY MATERIAL: PHOTOGRAPHIC ATLAS

## Morbilliform



a.

a. 44-year-old woman, Allergic to NSAIDs. No previous drugs. Morbilliform rash. Onset <24h after BNT162b2 first dose. Low-grade fever, headache, and asthenia. Resolved in 5 days. Treatment: oral antihistamines, plus oral and topical corticosteroids.



b. 71-year-old man. Dyslipidaemia and prostate hyperplasia. No previous drugs. Morbilliform rash. Onset 7 days after BNT162b2 first dose. Resolved in 7 days. Treatment: oral antihistamines and oral corticosteroids.




b.



d.

d. 61-year-old woman. Allergic to egg protein. No previous drugs. Morbilliform rash. Onset 3 days after AZD1222 first dose. Low-grade fever, myalgia and diarrhea. Resolved in 10 days. Treatment: oral antihistamines and topical corticosteroids.

c. 87-year-old woman Previous drugs: metamizole. Morbilliform rash. Onset 5 days after BNT162b2 first dose. Resolved in 20 days. Treatment: oral antihistamines.



c.

e. 49-year-old woman. Allergic to metamizole. No previous drugs. Morbilliform rash. Onset <24h after mRNA-127 second dose. Resolved in 7 days. Treatment: oral antihistamines and topical corticosteroids.



e.

# SUPPLEMENTARY MATERIAL: PHOTOGRAPHIC ATLAS

## Papulovesicular



a. 42-year-old woman. No previous drugs. Papulovesicular rash. Onset 10 days after mRNA-127 second dose. Low-grade fever. Resolved in 7 days. Treatment: oral antihistamines, topical corticosteroids and topical antibiotics. Same rash when she had COVID-19.

b. 21-year-old woman. No previous drugs. Papulovesicular rash. Onset 15 days after BNT162b2 first dose. Low-grade fever, myalgia and diarrhea. Resolved in 10 days. Treatment: oral antihistamines. Skin biopsy: lymphocytic vasculitis.



c. 35-year-old woman. No previous drugs. Papulovesicular rash. Onset 6 days after BNT162b2 first dose. Low-grade fever, myalgia and diarrhea. Resolved in 6 days. No treatment.

d. 63-year-old woman. No previous drugs. Papulovesicular rash. Onset 8 days after mRNA-127 first dose. Fever, myalgia and headache. Resolved in 60 days. Treatment: oral and topical corticosteroids.



# SUPPLEMENTARY MATERIAL: PHOTOGRAPHIC ATLAS

## Pityriasis rosea-like



a. 35-year-old man. Pityriasis rosea eruption. Onset 11 days after mRNA-127 first dose. Resolved in 7 days. Treatment: oral antihistamines and oral antibiotics. Skin biopsy: pityriasis rosea.



b. 77-year-old woman. Medical history: Chronic B lymphoid leukemia. No previous drugs. Pityriasis rosea eruption. Onset 3 days after BNT162b2 first dose. Resolved in 8 days. Treatment: oral antihistamines..

c. 41-year-old woman. No previous drugs. Pityriasis rosea eruption. Onset 9 days after BNT162b2 first dose. Resolved in 40 days. Treatment: topical Corticosteroids. Skin biopsy: pityriasis rosea.



d. 30-year-old man. Previously treated with acetaminophen. Pityriasis rosea eruption. Onset 2 days after BNT162b2 second dose. Resolved in 21 days. No treatment.

# SUPPLEMENTARY MATERIAL: PHOTOGRAPHIC ATLAS

## Purpuric



a. 64-year-old woman. No previous drugs. Purpuric eruption. Onset 7 days after AZD1222 first dose. Fever, asthenia and diarrhea. Resolved in 24 days. Treatment: oral corticosteroids.



b. 71-year-old woman. Allergic to codeine. Previous drugs: tapentadol. Purpuric eruption. Onset 7 days after BNT162b2 first dose. Resolved in 50 days. Treatment: oral corticosteroids.



c. 88-year-old man: Medical history: heart failure and cardiac arrhythmia on anticoagulants. Previous drugs: gabapentin. Purpuric eruption. Onset 5 days after BNT162b2 second dose. Resolved in 15 days. Treatment: oral and topical corticosteroids. Skin biopsy: toxicoderma.



d. 64-year-old woman. No previous drugs. Purpuric eruption. Onset 14 days after AZD1222 first dose. Resolved in 15 days. No treatment. Skin biopsy: leukocytoclastic vasculitis.



# SUPPLEMENTARY MATERIAL: PHOTOGRAPHIC ATLAS

## Varicella zoster virus reactivation



a. 89-year-old man. Thoracic herpes zoster. Onset 12 days after first dose BNT162b2 vaccine. It resolved after 30 days with oral antiviral and NSAIDs.



b. 48-year-old man. Facial herpes zoster. Onset 5 days after BNT162b2 first dose. Resolved in 10 days. Treatment: oral antiviral.



c. 93-year-old man. Lumbar herpes zoster. Onset 1 day after BNT162b2 second dose. Resolved in 10 days. Treatment: endovenous antiviral and topical antibiotics.



d. 22-year-old woman. Facial herpes zoster. Onset 15 days after AZD1222 first dose. Resolved in 20 days. Treatment: oral antiviral.

# SUPPLEMENTARY MATERIAL: PHOTOGRAPHIC ATLAS


## Herpes simplex virus reactivation



a. 58-year-old woman. Lip HVS reactivation. Onset 7 days after mRNA-127 first dose. Fever. Resolved in 5 days. Treatment: topical antiviral.



b. 35-year-old man. Chin HVS reactivation. Onset: 2 days after mRNA-127 second dose. Resolved in 7 days. No treatment.




c. 22-year-old woman. Intranasal and oral HVS reactivation. Onset 4 days after AZD1222 first dose. Fever, myalgia, asthenia, diarrhea, and headache. Resolved in 8 days. Treatment: oral antiviral.



d. 29-year-old woman. Lip HVS reactivation. Onset 2 days after mRNA-127 first . Resolved in 10 days. No treatment.

# SUPPLEMENTARY MATERIAL: PHOTOGRAPHIC ATLAS

## Other eruptions



a.

a. 39-year-old woman. No previous drugs. Erythema multiforme-like eruption. Onset 2 days after mRNA-127 first dose. Resolved in 15 days. Treatment topical corticosteroids.



b.

b. 52-year-old woman. No previous drugs. Raynaud-like eruption. Onset 6 days after AZD1222 first dose. Resolved in 30 days. Treatment: manidipine.



c.

c. 72-year-old man. Medical history: Chronic plaque psoriasis (no palmo plantar) treated with adalimumab. Psoriasis outbreak on palms and soles. Onset 3 days after BNT162b2 second dose. Resolved in 21 days. Treatment: topical and oral corticosteroids.

d. 58-year-old man. No previous drugs. Generalized pustular rash. Onset 3 days after BNT162b2 second dose. Resolved in 10 days. Treatment: topical corticosteroids and topical antibiotics. Skin biopsy: acute generalized exanthematous pustulosis.



d.

# SUPPLEMENTARY MATERIAL: PHOTOGRAPHIC ATLAS



e. 91-year-old man. No previous drugs. Bullous pemphigoid. Onset 24h after BNT162b2 second dose. Resolved in 35 days. Treatment: topical and oral corticosteroids. Skin biopsy: Bullous pemphigoid.



f. 67-year-old woman. No previous drugs. Symmetrical drug-related intertriginous and flexural exanthema (SDRIFE). Onset 24h after AZD1222 first dose. Fever. Resolved in 1 day. Treatment: topical and oral corticosteroids and antihistamines.